1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,609 | 0,640 | 22:21 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.01. | Cereno Scientific Announces First Peer-Reviewed Publication on HDAC Inhibitor CS014: Antithrombotic Efficacy Without Bleeding Risk Supports Broad Potential in Cardiopulmonary Diseases | 227 | PR Newswire | GOTHENBURG, Sweden, Jan. 14, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare... ► Artikel lesen | |
| 12.01. | Cereno Scientific - Entering a value inflection phase | 281 | Edison Investment Research | We refresh our investment case for Cereno Scientific as the company enters a key value inflection period, with its lead asset CS1 expected to initiate a Phase IIb study in Q226, followed by Phase II... ► Artikel lesen | |
| 08.01. | Cereno Scientific AB: Cereno Scientific Receives approximately SEK 5 million Through Exercise of 728,957 Warrants by Arena Investors, LP | 342 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B) ("the Company"), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, announces... ► Artikel lesen | |
| 18.12.25 | Cereno Scientific's Board of Directors and Management Enter Lock-up Agreements | 2 | Cision News | ||
| CERENO SCIENTIFIC Aktie jetzt für 0€ handeln | |||||
| 18.12.25 | Cereno Scientific to Host Capital Markets Day on February 5, 2026 | 2 | Cision News | ||
| 11.12.25 | Cereno Scientific - Runway clears for Phase IIb with FDA nod | 302 | Edison Investment Research | Cereno Scientific has announced that it has been granted FDA clearance for its global Phase IIb trial for CS1 in pulmonary arterial hypertension (PAH), clearing the way for trial initiation in Q226.... ► Artikel lesen | |
| 08.12.25 | Cereno Scientific Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension (PAH) | 335 | PR Newswire | GOTHENBURG, Sweden, Dec. 8, 2025 /PRNewswire/ -- Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare... ► Artikel lesen | |
| 03.12.25 | Cereno Scientific to Present New Data of CS014 at the Pharmacology 2025 on December 15-18 | 1 | Cision News | ||
| 02.12.25 | Cereno Scientific - Armed and ready for Phase II | 335 | Edison Investment Research | Cereno Scientific reported its Q325 results, a quarter focused on Phase II preparations for lead assets CS1 and CS014, following encouraging Phase I data for CS014, fast track designation for CS1 and... ► Artikel lesen | |
| 30.11.25 | Correction: Cereno Scientific Secures SEK 100m in Directed Share Issue and Loan Financing of SEK 350m Reaching Milestones in Q4-2027 | 1 | Cision News | ||
| 28.11.25 | Cereno Scientific AB: Cereno Scientific Secures SEK 100m in Directed Share Issue and Loan Financing of SEK 350m Reaching Milestones in Q4-2027 | 203 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA... ► Artikel lesen | |
| 28.11.25 | Cereno Scientific AB: Cereno Scientific: Major shareholders and new investors back the Company's long-term strategy with equity investment at a premium | 168 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B) (the "Company"), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, announced... ► Artikel lesen | |
| 27.11.25 | Cereno Scientific AB Loss At -SEK21.32 Mln In Q3 | - | RTTNews | ||
| 27.11.25 | Cereno Scientific AB: Cereno Scientific Publishes Interim Report for Q3 2025 (July 1 - September 30, 2025) | 251 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 10.11.25 | Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial Hypertension (PAH) to the U.S. FDA | 304 | PR Newswire | GOTHENBURG, Sweden, Nov. 10, 2025 /PRNewswire/ -- Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people... ► Artikel lesen | |
| 24.09.25 | Cereno Scientific Participates at Partnering and Investor Conference Nordic Life Science Days 2025 | 1 | Cision News | ||
| 15.09.25 | Cereno Scientific Announces Conversion of All Remaining Convertibles Following Request by Fenja Capital II A/S and Arena Investors, LP | 1 | Cision News | ||
| 03.09.25 | Cereno Scientific Announces Sten R. Sörensen Named Finalist for 'CEO of the Year' at the European Lifestars Awards 2025 | 1 | Cision News | ||
| 02.09.25 | Cereno Scientific Participates at GoCo Investor Day on September 9, 2025, in Gothenburg | 1 | Cision News | ||
| 27.08.25 | Cereno Scientific AB: Cereno Scientific Publishes Interim Report for Q2 2025 (April 1 - June 30, 2025) | 786 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 46,125 | -0,27 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat die Einstufung für Qiagen beim fairen Aktienwert von 50 Euro auf "Kaufen" belassen. Der Diagnostikspezialist habe seine Mittelfristziele für Wachstumstreiber... ► Artikel lesen | |
| ARCELLX | 68,62 | -0,36 % | Arcellx präsentiert Daten zu Anito-Cel auf den Tandem Meetings 2026 | ||
| EDGEWISE THERAPEUTICS | 29,780 | +1,88 % | Edgewise Therapeutics, Inc. (EWTX) Outlines Priorities For 2026 | ||
| BIONTECH | 100,70 | -0,30 % | Milliardenhoffnung: BioNTech greift mit Krebsforschung neu an: Goldman Sachs löst Kursschub mit optimistischem Onkologie-Ausblick aus | Die US-Investmentbank Goldman Sachs hat die Aktie von BioNTech deutlich hochgestuft. Statt auf das abklingende Impfstoffgeschäft konzentriert sich die Bewertung nun auf die wachstumsstarke Pipeline... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,370 | +3,09 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,970 | +7,58 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,530 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| ERASCA | 10,220 | +1,69 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 91,73 | -2,20 % | Guggenheim raises Structure Therapeutics stock price target to $140 on obesity drug confidence | ||
| BEAM THERAPEUTICS | 34,270 | +10,12 % | Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway | ||
| RELAY THERAPEUTICS | 7,600 | +0,80 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 | Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,74 | +0,14 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| JANUX THERAPEUTICS | 15,130 | +14,02 % | BMS Tries Again With T Cell Engagers, Turning to Janux to Develop New Tumor-Activated Therapy | ||
| CABALETTA BIO | 2,930 | +24,68 % | Cabaletta Bio shares climb after insider purchases | ||
| ENLIVEN THERAPEUTICS | 27,030 | -0,66 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen |
CERENO SCIENTIFIC AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,005 (-0,74 %) liegt der Kurs bei 0,603 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERENO SCIENTIFIC AB finden Sie auf Wallstreet Online.